Tripos International, the leading provider of drug discovery informatics products and services, today announced that it has completed the acquisition of Pharsight Corporation, a leader in software, strategic and regulatory services designed to optimize clinical drug development. The transaction, valued at approximately $57 million, moves Pharsight into the Tripos portfolio.

In making the announcement, Tripos’ President and Chief Executive Officer, Jim Hopkins said, “We’re excited to add Pharsight to the Tripos family. By acquiring Pharsight, we expect to provide our customers with important new products, key enabling technologies and scientific expertise, and to expedite the flow of information throughout discovery and development.”

“We’re very pleased to be part of Tripos team,” said Shawn O’Connor, Chairman and Chief Executive Officer at Pharsight. “This acquisition by Tripos means our clients will be better positioned to respond to all aspects of drug discovery, development and commercialization activities. The solutions spectrum is much broader now.”